Preventive Vaccine Market
Preventive Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type – Live Attenuated Vaccines, Inactivated Vaccines, Subunit & Recombinant Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines, By Disease Indication – Respiratory, Pediatric, Hepatitis, HPV, Meningococcal & Pneumococcal, Travel & Endemic Diseases, By Age Group, By Route of Administration, Forecast Period (2026–2035)
Industry Overview
Preventive vaccine Market was valued at USD 58.1 billion in 2025 and is projected to reach USD 96.5 billion by 2035, expanding at a CAGR of 5.2% during 2026 to 2035. The market is witnessing steady growth due to rising global immunization initiatives, increasing prevalence of infectious diseases, and advancements in biotechnology such as mRNA and viral vector platforms. According to the World Health Organization (WHO), vaccination prevents approximately 3.5–5 million deaths annually from diseases such as influenza, measles, and diphtheria, reinforcing the critical role of preventive vaccines in global public health systems. Expanding government immunisation programs and increased funding from international organisations are further strengthening demand. Key end-use sectors include public healthcare systems, hospitals, clinics, vaccination centres, and international travel medicine services. Rising awareness regarding preventive healthcare and the integration of advanced vaccine technologies are shaping long-term market expansion. Pharmaceutical manufacturers are focusing on scalable production and cold-chain optimisation to improve global accessibility, especially in developing economies.
Market Dynamics
Driver: Rising Global Immunisation Programs and Biotech Advancements
The preventive vaccine market is primarily driven by large-scale immunisation initiatives supported by global health organisations such as the WHO and UNICEF, which aim to improve vaccine coverage in developing regions. The increasing prevalence of infectious diseases, including influenza, HPV, and pneumococcal infections, is boosting vaccine demand worldwide. The expansion of mRNA-based vaccine technologies has significantly enhanced development speed and efficacy, as seen in post-pandemic innovation cycles. Governments across the US, EU, and Asia-Pacific are increasing healthcare spending to strengthen immunisation infrastructure. Pharmaceutical companies such as Pfizer, GSK, and Moderna are investing heavily in R&D, focusing on combination vaccines and next-generation platforms. Additionally, rising awareness of preventive healthcare and mandatory vaccination policies in several countries is accelerating market penetration. This strong policy and technological ecosystem are expected to sustain long-term growth across both developed and emerging markets.
Cold Chain Logistics and High Development Costs
Despite strong demand, the preventive vaccine market faces significant challenges related to cold chain logistics, manufacturing complexity, and high development costs. Many vaccines, particularly mRNA-based formulations, require ultra-cold storage conditions, limiting distribution in low-resource regions. According to global health logistics studies, nearly 25% of vaccines are estimated to be wasted annually due to supply chain inefficiencies. In addition, stringent regulatory approval processes by agencies such as the FDA and EMA increase time-to-market for new vaccines. High R&D costs and long clinical trial timelines also restrict entry for smaller biotechnology firms. Companies are responding by investing in thermostable vaccine formulations, decentralised manufacturing units, and AI-driven clinical trial optimisation. However, balancing affordability with innovation remains a key industry challenge.
Market Segmentation
- Based on the vaccine type, the market is segmented into live attenuated vaccines, inactivated vaccines, subunit and recombinant vaccines, toxoid vaccines, mRNA vaccines, and viral vector vaccines.
• Based on the disease indication, the market is segmented into respiratory diseases, pediatric diseases, hepatitis, HPV, meningococcal and pneumococcal diseases, and travel & endemic diseases.
• Based on the age group, the market is segmented into pediatric, adult, and geriatric populations.
• Based on the route of administration, the market is segmented into injectable, oral, and nasal vaccines.
Inactivated Vaccines Segment Leads the Market
Inactivated vaccines dominate the preventive vaccine market due to their established safety profile, stability, and wide usage in national immunization programs. These vaccines are extensively used for influenza, hepatitis, and polio prevention. Governments and healthcare agencies prefer inactivated vaccines due to a lower risk of infection and easier storage compared to live attenuated forms. Between 2022 and 2026, companies such as Sanofi and GSK have expanded production capacity for influenza and combination vaccines to meet rising global demand. Additionally, strong adoption in pediatric and elderly populations supports consistent market leadership. The segment benefits from well-established manufacturing infrastructure and regulatory familiarity, ensuring continued dominance in global immunization strategies.
mRNA Vaccines Segment to Record Strong Growth
The mRNA vaccines segment is expected to witness the fastest growth during the forecast period due to technological breakthroughs and rapid development capabilities. These vaccines offer high adaptability for emerging infectious diseases, reducing development timelines significantly. Pharmaceutical firms such as Moderna and Pfizer are heavily investing in mRNA platforms for influenza, RSV, and combination vaccines. Increasing government funding for pandemic preparedness and biotech innovation is further accelerating adoption. Additionally, mRNA technology enables scalable production and faster response to viral mutations, making it highly suitable for future epidemic control strategies. Rising clinical trials and expanding regulatory approvals are expected to drive strong investment inflows into this segment globally.
Regional Outlook
The global preventive vaccine market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
North America to Dominate the Market
North America is the leading region in the preventive vaccine market, driven mainly by the United States due to the strong presence of major vaccine manufacturers like Pfizer, Moderna, and Merck & Co., along with high vaccination coverage, advanced healthcare infrastructure, and premium pricing of vaccines. The region also benefits from continuous innovation and strong government immunization programs, making it the highest revenue contributor globally.
Asia-Pacific to Record Strong Growth
Asia-Pacific is the fastest-growing region in the preventive vaccine market, led by countries such as India and China, due to large population size and expanding immunization coverage. Governments across the region are significantly increasing investments in national vaccination programs to control infectious diseases. The presence of major regional manufacturers like Serum Institute of India and Sinovac Biotech supports large-scale, cost-effective vaccine production. There is also a rising shift toward the adoption of advanced vaccines such as HPV, pneumococcal, and influenza vaccines. Improving healthcare infrastructure, increasing awareness, and growing private sector participation are further accelerating market growth. Moreover, the region is becoming a global hub for vaccine exports, contributing to both volume expansion and international market influence.
Competitive Landscape
The preventive vaccine market is highly competitive and innovation-driven, dominated by global pharmaceutical giants focusing on advanced vaccine platforms, strategic collaborations, and capacity expansion. Companies are investing heavily in mRNA technology, recombinant platforms, and AI-based drug discovery to accelerate vaccine development timelines. Major players such as GSK plc, Merck & Co., Pfizer Inc., Sanofi, and Moderna are actively engaged in expanding global manufacturing capacity and strengthening distribution networks. Competition is intensifying due to rising demand for combination vaccines and rapid-response immunisation solutions. Strategic partnerships between biotech firms and governments are also shaping the competitive structure of the market, ensuring faster vaccine deployment and broader accessibility across regions.
Recent Developments (2025–2026)
- In March 2026, Serum Institute of India entered into a strategic collaboration with Eveliqure Biotechnologies to develop and commercialize novel anti-diarrhoeal vaccines, along with multiple licensing agreements with institutions like the University of Oxford for emerging infectious disease vaccines (e.g., Nipah virus). This expansion highlights how vaccine manufacturers are strengthening their pipelines through partnerships and licensing deals to address unmet preventive needs and expand their global vaccine portfolios.
- In August 2025, Novavax announced the FDA approval of its updated Nuvaxovid COVID-19 vaccine (2025–2026 formula) for the prevention of COVID-19 in high-risk populations. The vaccine is a protein-based, non-mRNA preventive vaccine, positioned as an alternative to mRNA platforms, and is tailored to target emerging variants such as the JN.1 lineage. This launch reflects continuous product innovation and seasonal vaccine updates in the preventive vaccine market, ensuring alignment with circulating strains and expanding immunization options for vulnerable populations.
The Report Covers
• Market value data analysis of 2025 and forecast to 2035.
• Annualised market revenues (USD billion) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global preventive vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
• Global Preventive Vaccine Market Sales Analysis – Vaccine Type | Disease Indication | Age Group | Route of Administration ($ Million)
• Preventive Vaccine Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
• Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Preventive Vaccine Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Preventive Vaccine Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers for Global Preventive Vaccine Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints for Global Preventive Vaccine Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities for Global Preventive Vaccine Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Preventive Vaccine Market Revenue and Share by Manufacturers
- Preventive Vaccine Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 GSK plc
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Merck & Co. Inc.
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Pfizer Inc.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Sanofi
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Moderna
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Preventive Vaccine Market Sales Analysis by Vaccine Type ($ Million)
5.1 Live Attenuated Vaccines
5.2 Inactivated (Killed) Vaccines
5.3 Subunit, Recombinant & Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 mRNA Vaccines
5.6 Viral Vector Vaccines
- Global Preventive Vaccine Market Sales Analysis by Disease Indication ($ Million)
6.1 Respiratory Diseases (Influenza, COVID-19, Pneumonia)
6.2 Pediatric Diseases (MMR, Polio, DTP)
6.3 Hepatitis (A, B)
6.4 HPV (Human Papillomavirus)
6.5 Meningococcal & Pneumococcal Diseases
6.6 Travel & Endemic Diseases (Yellow Fever, Typhoid, Rabies)
- Global Preventive Vaccine Market Sales Analysis by Age Group ($ Million)
7.1 Pediatric (0–17 years)
7.2 Adult (18–64 years)
7.3 Geriatric (65+ years)
- Global Preventive Vaccine Market Sales Analysis by Route of Administration ($ Million)
8.1 Injectable
8.2 Oral Vaccines
8.3 Nasal Vaccines
- Regional Analysis
9.1 North American Preventive Vaccine Market Sales Analysis – Vaccine Type | Disease Indication | Age Group | Route of Administration| Country ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Preventive Vaccine Market Sales Analysis – Vaccine Type | Disease Indication | Age Group | Route of Administration ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Preventive Vaccine Market Sales Analysis – Vaccine Type | Disease Indication | Age Group | Route of Administration| Country ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Preventive Vaccine Market Sales Analysis – Vaccine Type | Disease Indication | Age Group | Route of Administration| Country ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 AstraZeneca
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 Bavarian Nordic
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Bharat Biotech
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 BioNTech
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 CanSino Biologics
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Chongqing Zhifei Bio
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 CSL (CSL Seqirus)
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Daiichi Sankyo
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Emergent BioSolutions
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Hualan Biological Vaccine
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Indian Immunologicals (IIL)
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Mitsubishi Tanabe (Biken)
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Novavax
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Panacea Biotec
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Serum Institute of India
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Sinopharm (CNBG)
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Sinovac Biotech
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 Takeda Pharmaceutical
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Valneva
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 Walvax Biotechnology
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1 Global Preventive Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
2 Global Live Attenuated Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
3 Global Inactivated (Killed) Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
4 Global Subunit, Recombinant & Conjugate Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
5 Global Toxoid Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
6 Global mRNA Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
7 Global Viral Vector Vaccines Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
8 Global Preventive Vaccine Market Research and Analysis by Disease Indication, 2025–2035 ($ Million)
9 Global Preventive Vaccine for Respiratory Diseases Market Research and Analysis by Region, 2025–2035 ($ Million)
10 Global Preventive Vaccine for Pediatric Diseases Market Research and Analysis by Region, 2025–2035 ($ Million)
11 Global Preventive Vaccine for Hepatitis Market Research and Analysis by Region, 2025–2035 ($ Million)
12 Global Preventive Vaccine for HPV Market Research and Analysis by Region, 2025–2035 ($ Million)
13 Global Preventive Vaccine for Meningococcal & Pneumococcal Diseases Market Research and Analysis by Region, 2025–2035 ($ Million)
14 Global Preventive Vaccine for Travel & Endemic Diseases Market Research and Analysis by Region, 2025–2035 ($ Million)
15 Global Preventive Vaccine Market Research and Analysis by Age Group, 2025–2035 ($ Million)
16 Global Pediatric Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
17 Global Adult Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
18 Global Geriatric Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
19 Global Preventive Vaccine Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
20 Global Injectable Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
21 Global Oral Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
22 Global Nasal Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
23 Global Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
24 North America Preventive Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
25 North America Preventive Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
26 North America Preventive Vaccine Market Research and Analysis by Disease Indication, 2025–2035 ($ Million)
27 North America Preventive Vaccine Market Research and Analysis by Age Group, 2025–2035 ($ Million)
28 North America Preventive Vaccine Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
29 Europe Preventive Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
30 Europe Preventive Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
31 Europe Preventive Vaccine Market Research and Analysis by Disease Indication, 2025–2035 ($ Million)
32 Europe Preventive Vaccine Market Research and Analysis by Age Group, 2025–2035 ($ Million)
33 Europe Preventive Vaccine Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
34 Asia-Pacific Preventive Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
35 Asia-Pacific Preventive Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
36 Asia-Pacific Preventive Vaccine Market Research and Analysis by Disease Indication, 2025–2035 ($ Million)
37 Asia-Pacific Preventive Vaccine Market Research and Analysis by Age Group, 2025–2035 ($ Million)
38 Asia-Pacific Preventive Vaccine Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
39 Rest of the World Preventive Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
40 Rest of the World Preventive Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
41 Rest of the World Preventive Vaccine Market Research and Analysis by Disease Indication, 2025–2035 ($ Million)
42 Rest of the World Preventive Vaccine Market Research and Analysis by Age Group, 2025–2035 ($ Million)
43 Rest of the World Preventive Vaccine Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
1 Global Preventive Vaccine Market Share by Vaccine Type, 2025 Vs 2035 (%)
2 Global Live Attenuated Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
3 Global Inactivated (Killed) Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
4 Global Subunit, Recombinant & Conjugate Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
5 Global Toxoid Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
6 Global mRNA Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
7 Global Viral Vector Vaccines Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
8 Global Preventive Vaccine Market Share by Disease Indication, 2025 Vs 2035 (%)
9 Global Preventive Vaccine for Respiratory Diseases Share by Region, 2025 Vs 2035 (%)
10 Global Preventive Vaccine for Pediatric Diseases Share by Region, 2025 Vs 2035 (%)
11 Global Preventive Vaccine for Hepatitis Share by Region, 2025 Vs 2035 (%)
12 Global Preventive Vaccine for HPV Share by Region, 2025 Vs 2035 (%)
13 Global Preventive Vaccine for Meningococcal & Pneumococcal Diseases Share by Region, 2025 Vs 2035 (%)
14 Global Preventive Vaccine for Travel & Endemic Diseases Share by Region, 2025 Vs 2035 (%)
15 Global Preventive Vaccine Market Share by Age Group, 2025 Vs 2035 (%)
16 Global Pediatric Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
17 Global Adult Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
18 Global Geriatric Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
19 Global Preventive Vaccine Market Share by Route of Administration, 2025 Vs 2035 (%)
20 Global Injectable Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
21 Global Oral Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
22 Global Nasal Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
23 Global Preventive Vaccine Market Share by Region, 2025 Vs 2035 (%)
24 US Preventive Vaccine Market Size, 2025–2035 ($ Million)
25 Canada Preventive Vaccine Market Size, 2025–2035 ($ Million)
26 UK Preventive Vaccine Market Size, 2025–2035 ($ Million)
27 France Preventive Vaccine Market Size, 2025–2035 ($ Million)
28 Germany Preventive Vaccine Market Size, 2025–2035 ($ Million)
29 Italy Preventive Vaccine Market Size, 2025–2035 ($ Million)
30 Spain Preventive Vaccine Market Size, 2025–2035 ($ Million)
31 Russia Preventive Vaccine Market Size, 2025–2035 ($ Million)
32 India Preventive Vaccine Market Size, 2025–2035 ($ Million)
33 China Preventive Vaccine Market Size, 2025–2035 ($ Million)
34 Japan Preventive Vaccine Market Size, 2025–2035 ($ Million)
35 South Korea Preventive Vaccine Market Size, 2025–2035 ($ Million)
36 Australia & New Zealand Preventive Vaccine Market Size, 2025–2035 ($ Million)
37 ASEAN Preventive Vaccine Market Size, 2025–2035 ($ Million)
38 Rest of Asia-Pacific Preventive Vaccine Market Size, 2025–2035 ($ Million)
39 Latin America Preventive Vaccine Market Size, 2025–2035 ($ Million)
40 Middle East & Africa Preventive Vaccine Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
